Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AE06 LOPINAVIRUM + CAPS. MOI 133.3 mg/33.3 mg

RITONAVIRUM

KALETRA 133.3 mg/33.3 mg 133.3 mg/33.3 mg ABBOTT LABORATORIES LTD.

J05AE06 LOPINAVIRUM + COMPR. FILM. 200 mg/50 mg

RITONAVIRUM

KALETRA 200 mg/50 mg 200 mg/50 mg ABBOTT LABORATORIES LTD.
J05AE06 LOPINAVIRUM + SOL. ORALĂ 80 mg/ml + 20 mg/ml

RITONAVIRUM

KALETRA 80 mg/ml + 20 mg/ml 80 mg/ml + 20 mg/ml ABBOTT LABORATORIES LTD.

________________________________________________________________________________

______________________________________________________________________________

| 606 |J05AE07| FOSAMPRENAVIRUM** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AE07 FOSAMPRENAVIRUM COMPR. FILM. 700 mg

TELZIR 700 mg 700 mg GLAXO GROUP LTD.

________________________________________________________________________________

______________________________________________________________________________

| 607 |J05AE08| ATAZANAVIRUM | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul combinat al infecţiei HIV cu două sau mai multe antiretrovirale la pacienţii cu: celule CD4 < 500 pe mm cub sau încărcare virală > 10.000 copii per ml.